 |
|
|
REFERENCES
1.
Cohen MM, Duncan PG, Tate RB: Does anesthesia contribute
to operative mortality? JAMA 260:2859–2863, 1988.
2.
Fragen R: Diprivan (propofol): A historical perspective.
Semin Anesth 7:1, 1988.
3.
Kay B, Rolly G: I.C.I. 35868, a new intravenous
induction agent. Acta Anaesthesiol Belg 28:303–316, 1977.
4.
Briggs LP, Clarke RS, Watkins J: An adverse reaction
to the administration of disoprofol (Diprivan). Anaesthesia 37:1099–1101,
1982.
5.
James R, Glen JB: Synthesis, biological evaluation,
and preliminary structure-activity considerations of a series of alkylphenols as
intravenous anesthetic agents. J Med Chem 23:1350–1357, 1980.
6.
Simons P, Cockshott I, Douglas E: Blood concentrations,
metabolism and elimination after a subanesthetic intravenous dose of (14)C-propofol
(Diprivan) to male volunteers [abstract]. Postgrad Med J 61:64, 1985.
7.
Veroli P, O'Kelly B, Bertrand F, et al: Extrahepatic
metabolism of propofol in man during the anhepatic phase of orthotopic liver transplantation.
Br J Anaesth 68:183–186, 1992.
8.
Gray PA, Park GR, Cockshott ID, et al: Propofol
metabolism in man during the anhepatic and reperfusion phases of liver transplantation.
Xenobiotica 22:105–114, 1992.
9.
Kuipers JA, Boer F, Olieman W, et al: First-pass
lung uptake and pulmonary clearance of propofol: Assessment with a recirculatory
indocyanine green pharmacokinetic model. Anesthesiology 91:1780–1787, 1999.
10.
Dawidowicz AL, Fornal E, Mardarowicz M, Fijalkowska
A: The role of human lungs in the biotransformation of propofol. Anesthesiology
93:992–997, 2000.
11.
Raoof AA, van Obbergh LJ, de Ville de Goyet J,
Verbeeck RK: Extrahepatic glucuronidation of propofol in man: Possible contribution
of gut wall and kidney. Eur J Clin Pharmacol 50:91–96, 1996.
12.
Chen TL, Ueng TH, Chen SH, et al: Human cytochrome
P450 mono-oxygenase system is suppressed by propofol. Br J Anaesth 74:558–562,
1995.
13.
Adam HK, Briggs LP, Bahar M, et al: Pharmacokinetic
evaluation of ICI 35 868 in man. Single induction doses with different rates of
injection. Br J Anaesth 55:97–103, 1983.
14.
Kay NH, Sear JW, Uppington J, et al: Disposition
of propofol in patients undergoing surgery. A comparison in men and women. Br J
Anaesth 58:1075–1079, 1986.
15.
Kirkpatrick T, Cockshott ID, Douglas EJ, Nimmo
WS: Pharmacokinetics of propofol (Diprivan) in elderly patients. Br J Anaesth 60:146–150,
1988.
16.
Gepts E, Camu F, Cockshott ID, Douglas EJ: Disposition
of propofol administered as constant rate intravenous infusions in humans. Anesth
Analg 66:1256–1263, 1987.
17.
Schuttler J, Stoeckel H, Schwilden H: Pharmacokinetic
and pharmacodynamic modeling of propofol ('Diprivan') in volunteers and surgical
patients. Postgrad Med J 61 (Suppl 3):53–54, 1985.
18.
Shafer A, Doze VA, Shafer SL, White PF: Pharmacokinetics
and pharmacodynamics of propofol infusions during general anesthesia. Anesthesiology
69:348–356, 1988.
19.
Dyck JB, Maze M, Haack C, et al: Computer-controlled
infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers.
Anesthesiology 78:821–828, 1993.
20.
Venn RM, Karol MD, Grounds RM: Pharmacokinetics
of dexmedetomidine infusions for sedation of postoperative patients requiring intensive
care. Br J Anaesth 88:669–675, 2002.
21.
Reves J: Benzodiazepines. In
Prys-Roberts CH (ed): Pharmacokinetics of Anesthesia. Boston, Blackwell, 1984,
p 157.
22.
Fischler M, Bonnet F, Trang H, et al: The pharmacokinetics
of droperidol in anesthetized patients. Anesthesiology 64:486–489, 1986.
23.
Cressman WA, Plostnieks J, Johnson PC: Absorption,
metabolism and excretion of droperidol by human subjects following intramuscular
and intravenous administration. Anesthesiology 38:363–369, 1973.
24.
Fragen RJ, Avram MJ, Henthorn TK, Caldwell NJ:
A pharmacokinetically designed etomidate infusion regimen for hypnosis. Anesth
Analg 62:654–660, 1983.
25.
Schuttler J, Schwilden H, Stoeckel H: Infusion
strategies to investigate the pharmacokinetics and pharmacodynamics of hypnotic drugs:
Etomidate as an example. Eur J Anaesthesiol 2:133–142, 1985.
26.
Hebron BS, Edbrooke DL, Newby DM, Mather SJ: Pharmacokinetics
of etomidate associated with prolonged i.v. infusion. Br J Anaesth 55:281–287,
1983.
27.
de Ruiter G, Popescu DT, de Boer AG, et al: Pharmacokinetics
of etomidate in surgical patients. Arch Int Pharmacodyn Ther 249:180–188,
1981.
28.
Van Hamme MJ, Ghoneim MM, Ambre JJ: Pharmacokinetics
of etomidate, a new intravenous anesthetic. Anesthesiology 49:274–277, 1978.
29.
Forster A, Gardaz JP, Suter PM, Gemperle M: I.V.
midazolam as an induction agent for anaesthesia: A study in volunteers. Br J Anaesth
52:907–911, 1980.
30.
Norton AC, Dundas CR: Induction agents for day-case
anaesthesia. A double-blind comparison of propofol and midazolam antagonised by
flumazenil. Anaesthesia 45:198–203, 1990.
31.
Clements JA, Nimmo WS: Pharmacokinetics and analgesic
effect of ketamine in man. Br J Anaesth 53:27–30, 1981.
32.
Bremier D: Pharmacokinetics of methohexitone following
intravenous infusions in humans. Br J Anaesth 48:643, 1976.
33.
Hudson RJ, Stanski DR, Burch PG: Pharmacokinetics
of methohexital and thiopental in surgical patients. Anesthesiology 59:215–219,
1983.
34.
Philip BK, Simpson TH, Hauch MA, Mallampati SR:
Flumazenil reverses sedation after midazolam-induced general anesthesia in ambulatory
surgery patients. Anesth Analg 71:371–376, 1990.
35.
Mandema JW, Tuk B, van Steveninck AL, et al: Pharmacokinetic-pharmacodynamic
modeling of the central nervous system effects of midazolam and its main metabolite
alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 51:715–728,
1992.
36.
Bauer TM, Ritz R, Haberthur C, et al: Prolonged
sedation due to accumulation of conjugated metabolites of midazolam. Lancet 346:145–147,
1995.
37.
Greenblatt DJ, Shader RI, Divoll M, Harmatz JS:
Benzodiazepines: A summary of pharmacokinetic properties. Br J Clin Pharmacol
11(Suppl 1):11S–16S, 1981.
38.
MacLeod SM, Giles HG, Bengert B, et al: Age- and
gender-related differences in diazepam pharmacokinetics. J Clin Pharmacol 19:15–19,
1979.
39.
Greenblatt DJ, Abernethy DR, Locniskar A, et al:
Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61:27–35,
1984.
40.
Mould DR, DeFeo TM, Reele S, et al: Simultaneous
modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam.
Clin Pharmacol Ther 58:35–43, 1995.
41.
Bischoff KB, Dedrick RL: Thiopental pharmacokinetics.
J Pharm Sci 57:1346–1351, 1968.
42.
Christensen J, Andreasen F, Jansen J: Pharmacokinetics
of thiopentone in a group of young women and a group of young men. Br J Anaesth
52:913–918, 1980.
43.
Bailie GR, Cockshott ID, Douglas EJ, Bowles BJ:
Pharmacokinetics of propofol during and after long-term continuous infusion for
maintenance of sedation in ICU patients. Br J Anaesth 68:486–491, 1992.
44.
Hughes MA, Glass PS, Jacobs JR: Context-sensitive
half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs.
Anesthesiology 76:334–341, 1992.
45.
Dyck J, Varvel J, Hung O: The pharmacokinetics
of propofol vs. age. Anesthesiology 75:A315, 1991.
46.
Kazama T, Ikeda K, Morita K, et al: Comparison
of the effect-site k(e0)s of propofol for blood pressure and EEG bispectral index
in elderly and younger patients. Anesthesiology 90:1517–1527, 1999.
47.
Schnider TW, Minto CF, Shafer SL, et al: The influence
of age on propofol pharmacodynamics. Anesthesiology 90:1502–1516, 1999.
48.
Servin F, Desmonts JM, Farinotti R, et al: Pharmacokinetics
of the continuous infusion of propofol in the cirrhotic patient. Preliminary results
[in French]. Ann Fr Anesth Reanim 6:228–289, 1987.
49.
Morcos WE, Payne J: The induction of anaesthesia
with propofol ('Diprivan') compared in normal and renal failure patients. Postgrad
Med J 61(Suppl 3):62–63, 1985.
50.
Leslie K, Sessler DI, Bjorksten AR, Moayeri A:
Mild hypothermia alters propofol pharmacokinetics and increases the duration of
action of atracurium. Anesth Analg 80:1007–1014, 1995.
51.
Upton RN, Ludbrook GL, Grant C, Martinez AM: Cardiac
output is a determinant of the initial concentrations of propofol after short-infusion
administration. Anesth Analg 89:545–552, 1999.
52.
Kurita T, Morita K, Kazama T, Sato S: Influence
of cardiac output on plasma propofol concentrations during constant infusion in swine.
Anesthesiology 96:1498–1503, 2002.
53.
Kazama T, Kurita T, Morita K, et al: Influence
of hemorrhage on propofol pseudo-steady state concentration. Anesthesiology 97:1156–1161,
2002.
54.
Bailey JM, Mora CT, Shafer SL: Pharmacokinetics
of propofol in adult patients undergoing coronary revascularization. The Multicenter
Study of Perioperative Ischemia Research Group. Anesthesiology 84:1288–1297,
1996.
55.
Marsh B, White M, Morton N, Kenny GN: Pharmacokinetic
model driven infusion of propofol in children. Br J Anaesth 67:41–48, 1991.
56.
Kataria BK, Ved SA, Nicodemus HF, et al: The pharmacokinetics
of propofol in children using three different data analysis approaches. Anesthesiology
80:104–122, 1994.
57.
Murat I, Billard V, Vernois J, et al: Pharmacokinetics
of propofol after a single dose in children aged 1–3 years with minor burns.
Comparison of three data analysis approaches. Anesthesiology 84:526–532,
1996.
58.
Benoni G, Cuzzolin L, Gilli E: Pharmacokinetics
of propofol: Influence of fentanyl administration [abstract]. Eur J Anaesthesiol
183:1457, 1990.
59.
Pavlin DJ, Coda B, Shen DD, et al: Effects of
combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis
in human volunteers. Anesthesiology 84:23–37, 1996.
60.
Gill SS, Wright EM, Reilly CS: Pharmacokinetic
interaction of propofol and fentanyl: Single bolus injection study. Br J Anaesth
65:760–765, 1990.
61.
Matot I, Neely CF, Katz RY, Marshall BE: Fentanyl
and propofol uptake by the lung: Effect of time between injections. Acta Anaesthesiol
Scand 38:711–715, 1994.
62.
Janicki PK, James MF, Erskine WA: Propofol inhibits
enzymatic degradation of alfentanil and sufentanil by isolated liver microsomes in
vitro. Br J Anaesth 68:311–312, 1992.
63.
Krasowski MD, Nishikawa K, Nikolaeva N, et al:
Methionine 286 in transmembrane domain 3 of the GABAA
receptor beta subunit
controls a binding cavity for propofol and other alkylphenol general anesthetics.
Neuropharmacology 41:952–964, 2001.
64.
Jurd R, Arras M, Lambert S, Drexler B: General
anesthetic actions in vivo strongly attenuated by a point mutation in the GABAA
receptor beta3 subunit. FASEB J 17:250–252, 2003.
65.
Lam DW, Reynolds JN: Modulatory and direct effects
of propofol on recombinant GABAA
receptors expressed in Xenopus
oocytes: Influence of alpha- and gamma2
-subunits. Brain Res 784:179–187,
1998.
66.
Kikuchi T, Wang Y, Sato K, Okumura F: In vivo
effects of propofol on acetylcholine release from the frontal cortex, hippocampus
and striatum studied by intracerebral microdialysis in freely moving rats. Br J
Anaesth 80:644–648, 1998.
67.
Pain L, Jeltsch H, Lehmann O, et al: Central cholinergic
depletion induced by 192 IgG-saporin alleviates the sedative effects of propofol
in rats. Br J Anaesth 85:869–873, 2000.
68.
Kushikata T, Hirota K, Yoshida H, et al: Alpha-2
adrenoceptor activity affects propofol-induced sleep time. Anesth Analg 94:1201–1206,
2002.
69.
Lingamaneni R, Birch ML, Hemmings HC Jr: Widespread
inhibition of sodium channel-dependent glutamate release from isolated nerve terminals
by isoflurane and propofol. Anesthesiology 95:1460–1466, 2001.
70.
Antognini J, Wang X, Piercy M, Carstens E: Propofol
directly depresses lumbar dorsal horn neuronal responses to noxious stimulation in
goats. Can J Anaesth 47:273–279, 2000.
71.
Dong XP, Xu TL: The actions of propofol on gamma-aminobutyric
acid-A and glycine receptors in acutely dissociated spinal dorsal horn neurons of
the rat. Anesth Analg 95:907–914, 2002.
72.
Tonner PH, Poppers DM, Miller KW: The general
anesthetic potency of propofol and its dependence on hydrostatic pressure. Anesthesiology
77:926–931, 1992.
73.
Briggs LP, Dundee JW, Bahar M, Clarke RS: Comparison
of the effect of diisopropyl phenol (ICI 35,868) and thiopentone on response to somatic
pain. Br J Anaesth 54:307–311, 1982.
74.
Canavero S, Bonicalzi V, Pagni CA, et al: Propofol
analgesia in central pain: Preliminary clinical observations. J Neurol 242:561–567,
1995.
75.
Pain L, Gobaille S, Schleef C, et al: In vivo
dopamine measurements in the nucleus accumbens after nonanesthetic and anesthetic
doses of propofol in rats. Anesth Analg 95:915–919, 2002.
76.
Cechetto DF, Diab T, Gibson CJ, Gelb AW: The effects
of propofol in the area postrema of rats. Anesth Analg 92:934–942, 2001.
77.
Major E, Verniquet AJ, Waddell TK, et al: A study
of three doses of ici 35 868 for induction and maintenance of anaesthesia. Br J
Anaesth 53:267–272, 1981.
78.
Rolly G, Versichelen L, Huyghe L, Mungroop H:
Effect of speed of injection on induction of anaesthesia using propofol. Br J Anaesth
57:743–746, 1985.
79.
Glass P, Ginsberg B, Hawkins E: Comparison of
sodium thiopental/isoflurane to propofol (delivered by means of a pharmacokinetic
model-driven device) for the induction, maintenance, and recovery from anesthesia.
Anesthesiology 69:A575, 1988.
80.
McClune S, McKay AC, Wright PM, et al: Synergistic
interaction between midazolam and propofol. Br J Anaesth 68:240–245, 1992.
81.
Short TG, Plummer JL, Chui PT: Hypnotic and anaesthetic
interactions between midazolam, propofol and alfentanil. Br J Anaesth 69:162–167,
1992.
82.
Adam HK, Kay B, Douglas EJ: Blood disoprofol levels
in anesthetised patients. Correlation of concentrations after single or repeated
doses with hypnotic activity. Anaesthesia 37:536–540, 1982.
83.
Aun CS, Short SM, Leung DH, Oh TE: Induction dose-response
of propofol in unpremedicated children. Br J Anaesth 68:64–67, 1992.
84.
Smith C, McEwan A, Jhaveri R: Reduction of propofol
Cp50
by fentanyl. Anesthesiology 81:820–828, 1994.
85.
Mackenzie N, Grant IS: Propofol for intravenous
sedation. Anaesthesia 42:3–6, 1987.
86.
Wilson E, Mackenzie N, Grant IS: A comparison
of propofol and midazolam by infusion to provide sedation in patients who receive
spinal anaesthesia. Anaesthesia 43(Suppl):91–94, 1988.
87.
Veselis RA, Reinsel RA, Wronski M, et al: EEG
and memory effects of low-dose infusions of propofol. Br J Anaesth 69:246–254,
1992.
88.
Zacny JP, Lichtor JL, Coalson DW, et al: Subjective
and psychomotor effects of subanesthetic doses of propofol in healthy volunteers.
Anesthesiology 76:696–702, 1992.
89.
Kelly JS, Roy RC: Intraoperative awareness with
propofol-oxygen total intravenous anesthesia for microlaryngeal surgery. Anesthesiology
77:207–209, 1992.
90.
Glass PS: Prevention of awareness during total
intravenous anesthesia. Anesthesiology 78:399–400, 1993.
91.
McDonald NJ, Mannion D, Lee P, et al: Mood evaluation
and outpatient anaesthesia. A comparison between propofol and thiopentone. Anaesthesia
43(Suppl):68–69, 1988.
92.
Nelson V: Hallucinations after propofol. Anaesthesia
43:170, 1988.
93.
Cameron A: Opisthotonos again. Anaesthesia 42:1124,
1987.
94.
Hazeaux C, Tisserant D, Vespignani H, et al: Electroencephalographic
changes produced by propofol [in French]. Ann Fr Anesth Reanim 6:261–266,
1987.
95.
Yate PM, Maynard DE, Major E, et al: Anaesthesia
with ICI 35,868 monitored by the cerebral function analysing monitor (CFAM). Eur
J Anaesthesiol 3:159–166, 1986.
96.
Glass PS, Bloom M, Kearse L, et al: Bispectral
analysis measures sedation and memory effects of propofol, midazolam, isoflurane,
and alfentanil in healthy volunteers. Anesthesiology 86:836–847, 1997.
97.
Maurette P, Simeon F, Castagnera L, et al: Propofol
anaesthesia alters somatosensory evoked cortical potentials. Anaesthesia 43(Suppl):44–45,
1988.
98.
Savoia G, Esposito C, Belfiore F, et al: Propofol
infusion and auditory evoked potentials. Anaesthesia 43(Suppl):46–49, 1988.
99.
Doi M, Gajraj RJ, Mantzaridis H, Kenny GN: Relationship
between calculated blood concentration of propofol and electrophysiological variables
during emergence from anaesthesia: Comparison of bispectral index, spectral edge
frequency, median frequency and auditory evoked potential index. Br J Anaesth 78:180–184,
1997.
100.
Glen JB, Hunter SC, Blackburn TP, Wood P: Interaction
studies and other investigations of the pharmacology of propofol ('Diprivan'). Postgrad
Med J 61(Suppl 3):7–14, 1985.
101.
al-Hader A, Hasan M, Hasan Z: The comparative
effects of propofol, thiopental, and diazepam, administered intravenously, on pentylenetetrazol
seizure threshold in the rabbit. Life Sci 51:779–786, 1992.
102.
Heavner J, Arthur J, Zou J: Propofol vs. thiopental
for treating bupivacaine induced seizures in rats. Anesthesiology 77:A802, 1992.
103.
Wood P, Browne G, Pugh S: Propofol infusion for
the treatment of status epilepticus [letter]. Lancet 1:480, 1988.
104.
Chilvers CR, Laurie PS: Successful use of propofol
in status epilepticus. Anaesthesia 45:995–996, 1990.
105.
Dwyer R, McCaughey W, Lavery J, et al: Comparison
of propofol and methohexitone as anaesthetic agents for electroconvulsive therapy.
Anaesthesia 43:459–462, 1988.
106.
Hodkinson BP, Frith RW, Mee EW: Propofol and
the electroencephalogram. Lancet 2:1518, 1987.
107.
Committee on Safety of Medicines: Propofol.
Curr Probl 20, 1987.
108.
Ebrahim ZY, Schubert A, Van Ness P, et al: The
effect of propofol on the electroencephalogram of patients with epilepsy. Anesth
Analg 78:275–279, 1994.
109.
Samra SK, Sneyd JR, Ross DA, Henry TR: Effects
of propofol sedation on seizures and intracranially recorded epileptiform activity
in patients with partial epilepsy. Anesthesiology 82:843–851, 1995.
110.
Anonymous: Convulsions after propofol. Pharm
J 249:745, 1992.
111.
Deer TR, Rich GF: Propofol tolerance in a pediatric
patient. Anesthesiology 77:828–829, 1992.
112.
Boyle W, Shear J, White P: Tolerance and hyperlipemia
during long term sedation with propofol. Anesthesiology 73:A245, 1990.
113.
Follette JW, Farley WJ: Anesthesiologist addicted
to propofol. Anesthesiology 77:817–818, 1992.
114.
Mendes PM, Silberstein SD, Young WB, et al: Intravenous
propofol in the treatment of refractory headache. Headache 42:638–641, 2002.
115.
Stephan H, Sonntag H, Schenk HD, Kohlhausen S:
Effect of Disoprivan (propofol) on the circulation and oxygen consumption of the
brain and CO2
reactivity of brain vessels in the human [in German]. Anaesthesist
36:60–65, 1987.
116.
Hartung HJ: Intracranial pressure in patients
with craniocerebral trauma after administration of propofol and thiopental [in German].
Anaesthesist 36:285–287, 1987.
117.
Hartung HJ: Modification of intracranial pressure
by propofol (Disoprivan). Initial results [in German]. Anaesthesist 36:66–68,
1987.
118.
Ravussin P, Guinard JP, Ralley F, Thorin D: Effect
of propofol on cerebrospinal fluid pressure and cerebral perfusion pressure in patients
undergoing craniotomy. Anaesthesia 43(Suppl):37–41, 1988.
119.
Vandesteene A, Trempont V, Engelman E, et al:
Effect of propofol on cerebral blood flow and metabolism in man. Anaesthesia 43(Suppl):42–43,
1988.
120.
Herregods L, Verbeke J, Rolly G, Colardyn F:
Effect of propofol on elevated intracranial pressure. Preliminary results. Anaesthesia
43(Suppl):107–109, 1988.
121.
Mirakhur R, Shepherd W: Intraocular pressure
changes with propofol ('Diprivan'): Comparison with thiopentone. Postgrad Med J
61(Suppl 3):41–44, 1985.
122.
Mirakhur RK, Shepherd WF, Darrah WC: Propofol
or thiopentone: Effects on intraocular pressure associated with induction of anaesthesia
and tracheal intubation (facilitated with suxamethonium). Br J Anaesth 59:431–436,
1987.
123.
Enns J, Gelb A, Manninen P: Cerebral autoregulation
is maintained during propofol-nitrous oxide anaesthesia in humans. Can J Anaesth
39:A43, 1992.
124.
Jansen G, Kagenaar D, Kedaria M: Effects of propofol
on the relation between CO2
and cerebral blood flow velocity. Anesth
Analg 76:S163, 1993.
125.
Newman MF, Murkin JM, Roach G, et al: Cerebral
physiologic effects of burst suppression doses of propofol during nonpulsatile cardiopulmonary
bypass. CNS Subgroup of McSPI. Anesth Analg 81:452–457, 1995.
126.
Kochs E, Hoffman WE, Werner C, et al: The effects
of propofol on brain electrical activity, neurologic outcome, and neuronal damage
following incomplete ischemia in rats. Anesthesiology 76:245–252, 1992.
127.
Gelb A, Zhang C, Henderson S: A comparison of
the cerebral protective effects of propofol, thiopental, and halothane in temporary
feline focal cerebral ischemia. Anesth Analg 76:S115, 1993.
128.
Ridenour TR, Warner DS, Todd MM, Gionet TX: Comparative
effects of propofol and halothane on outcome from temporary middle cerebral artery
occlusion in the rat. Anesthesiology 76:807–812, 1992.
129.
Gelb AW, Bayona NA, Wilson JX, Cechetto DF: Propofol
anesthesia compared to awake reduces infarct size in rats. Anesthesiology 96:1183–1190,
2002.
130.
Bhardwaj A, Castro IA, Alkayed NJ, et al: Anesthetic
choice of halothane versus propofol: Impact on experimental perioperative stroke.
Stroke 32:1920–1925, 2001.
131.
Kaptanoglu E, Sen S, Beskonakli E, et al: Antioxidant
actions and early ultrastructural findings of thiopental and propofol in experimental
spinal cord injury. J Neurosurg Anesthesiol 14:114–122, 2002.
132.
Amorim P, Chambers G, Cottrell J, Kass IS: Propofol
reduces neuronal transmission damage and attenuates the changes in calcium, potassium,
and sodium during hyperthermic anoxia in the rat hippocampal slice. Anesthesiology
83:1254–1265, 1995.
133.
Ergun R, Adkemir G, Sen S, et al: Neuroprotective
effects of propofol following global cerebral ischemia in rats. Neurosurg Rev 25:95–98,
2002.
134.
Lanigan C, Sury M, Bingham R, et al: Neurological
sequelae in children after prolonged propofol infusion. Anaesthesia 47:810–811,
1992.
135.
Trotter C, Serpell MG: Neurological sequelae
in children after prolonged propofol infusion. Anaesthesia 47:340–342, 1992.
136.
Spahr-Schopfer I, Vutskits L, Toni N, et al:
Differential neurotoxic effects of propofol on dissociated cortical cells and organotypic
hippocampal cultures. Anesthesiology 92:1408–1417, 2000.
137.
Vuyk J, Engbers FH, Lemmens HJ, et al: Pharmacodynamics
of propofol in female patients. Anesthesiology 77:3–9, 1992.
138.
Forrest FC, Tooley MA, Saunders PR, Prys-Roberts
C: Propofol infusion and the suppression of consciousness: The EEG and dose requirements.
Br J Anaesth 72:35–41, 1994.
139.
Turtle MJ, Cullen P, Prys-Roberts C, et al: Dose
requirements of propofol by infusion during nitrous oxide anaesthesia in man. II:
Patients premedicated with lorazepam. Br J Anaesth 59:283–287, 1987.
140.
Spelina KR, Coates DP, Monk CR, et al: Dose requirements
of propofol by infusion during nitrous oxide anaesthesia in man. I: Patients premedicated
with morphine sulphate. Br J Anaesth 58:1080–1084, 1986.
141.
Sanderson JH, Blades JF: Multicentre study of
propofol in day case surgery. Anaesthesia 43(Suppl):70–73, 1988.
142.
Kazama T, Ikeda K, Morita K, Sanjo Y: Awakening
propofol concentration with and without blood-effect site equilibration after short-term
and long-term administration of propofol and fentanyl anesthesia. Anesthesiology
88:928–934, 1998.
143.
Taylor MB, Grounds RM, Mulrooney PD, Morgan M:
Ventilatory effects of propofol during induction of anaesthesia. Comparison with
thiopentone. Anaesthesia 41:816–820, 1986.
144.
Goodman NW, Black AM, Carter JA: Some ventilatory
effects of propofol as sole anaesthetic agent. Br J Anaesth 59:1497–1503,
1987.
145.
Gold MI, Abraham EC, Herrington C: A controlled
investigation of propofol, thiopentone and methohexitone. Can J Anaesth 34:478–483,
1987.
146.
Munson ES, Larson CP Jr, Babad AA, et al: The
effects of halothane, fluroxene and cyclopropane on ventilation: A comparative study
in man. Anesthesiology 27:716–728, 1966.
147.
Knill RL, Clement JL, Gelb AW: Ventilatory responses
mediated by peripheral chemoreceptors in anaesthetized man. Adv Exp Med Biol 99:66–77,
1978.
148.
Aun C, Major E: The cardiorespiratory effects
of ICI 35 868 in patients with valvular heart disease. Anaesthesia 39:1096–1100,
1984.
149.
Grounds RM, Twigley AJ, Carli F, et al: The haemodynamic
effects of intravenous induction. Comparison of the effects of thiopentone and propofol.
Anaesthesia 40:735–740, 1985.
150.
Al-Khudhairi D, Gordon G, Morgan M, Whitwam JG:
Acute cardiovascular changes following disoprofol. Effects in heavily sedated patients
with coronary artery disease. Anaesthesia 37:1007–1010, 1982.
